I.
Completed Studies (with selected publications and
presentations)
A. The Healing and Early Afterload
Reducing Therapy Trial (HEART) – Sponsor, Hoechst-Marion Roussell
Pfeffer
MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace
FJ Jr, Rapaport E, Ridker
PM, Rouleau JL, Solomon SD, Hennekens CH. Early versus delayed angiotensin-converting
enzyme inhibition therapy in acute myocardial infarction. The
healing and early afterload reducing therapy trial.
Circulation. 1997 Jun 17;95(12):2643-51.
Solomon
SD, Glynn RJ, Greaves S, Ajani U, Rouleau JL, Menapace F, Arnold JM, Hennekens
C, Pfeffer MA. Recovery of ventricular
function after myocardial infarction in the reperfusion era: the healing and
early afterload reducing therapy study. Ann Intern
Med. 2001 Mar 20;134(6):451-8.
Greaves
SC, Zhi G, Lee RT, Solomon SD, MacFadyen
J, Rapaport E, Menapace FJ,
Rouleau JL, Pfeffer MA. Incidence and natural history of left ventricular thrombus
following anterior wall acute myocardial infarction.
Am J Cardiol. 1997 Aug 15;80(4):442-8.
Aikawa Y,
Rohde L, Plehn J, Greaves SC, Menapace
F, Arnold MO, Rouleau JL, Pfeffer MA, Lee RT, Solomon SD. Regional wall stress predicts ventricular
remodeling after anteroseptal myocardial infarction
in the Healing and Early Afterload Reducing Trial
(HEART): an echocardiography-based structural analysis. Am Heart J. 2001 Feb;141(2):234-42.
Manes C, Pfeffer MA, Rutherford JD, Greaves S, Rouleau
JL,
Jilaihawi
H, Greaves S, Rouleau JL, Pfeffer MA, Solomon SD; Healing and Early Afterload Reducing Therapy Trial Investigators. Left ventricular hypertrophy
and the risk of subsequent left ventricular remodeling following myocardial
infarction.
Am J Cardiol. 2003 Mar 15;91(6):723-6.
Manes
C, Greaves S, Pfeffer MA, Rutherford JD, Rouleau JL, Hennekens
C, Solomon SD. Influence of diabetes mellitus on clinical presentation and
development of heart failure following myocardial infarction. ACC 2004
B. The Survival and Ventricular Enlargement (SAVE)
Trial, Echocardiographic Analyses:
Zornoff
LA, Skali H, Pfeffer MA, St John Sutton M, Rouleau JL, Lamas GA, Plappert T, Rouleau JR, Moye LA,
Lewis SJ, Braunwald E, Solomon SD; SAVE
Investigators. Right ventricular dysfunction and risk of
heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002 May 1;39(9):1450-5.
Solomon
SD, St John Sutton M, Lamas GA, Plappert T, Rouleau
JL, Skali H, Moye L, Braunwald
E, Pfeffer MA; Survival And Ventricular Enlargement (SAVE) Investigators. Ventricular remodeling does not accompany the
development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002 Sep 3;106(10):1251-5.
Solomon SD,
Kenchaiah
S, Pfeffer MA, St John Sutton M, Plappert T, Rouleau
JL, Lamas GA, Sasson Z, Parker JO, Geltman EM, Solomon SD. Effect of antecedent
systemic hypertension on subsequent left ventricular dilation after acute
myocardial infarction (from the Survival and Ventricular Enlargement trial).
Am J Cardiol. 2004 Jul 1;94(1):1-8.
C. The Omapatrilat Versus Enalapril in Heart Failure
(OVERTURE) Trial: Sponsor,
Solomon
SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA; OVERTURE
Investigators. Effect of angiotensin-converting enzyme or vasopeptidase
inhibition on ventricular size and function in patients with heart failure: the
Omapatrilat Versus Enalapril
Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic
study. Am Heart J. 2005 Aug;150(2):257-62.
Crivaro
M, Kenchaiah S, Bourgoun M, Skali H, Ghali JK, Pfeffer MA, Solomon SD. Functional mitral regurgitation and risk of heart failure in patients
with left ventricular dysfunction. The OVERTURE Echo study.
Presented ACC 2004
D. The Valsartan in Acute
Infarction (VALIANT) trial Echocardiographic Study: Sponsor, Novartis;
Solomon
SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in
patients treated with valsartan, captopril, or both
after myocardial infarction. Circulation. 2005 Jun 28;111(25):3411-9.
Epub 2005 Jun 20.
Anavekar N, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJV, Velazquez E, Pfeffer MA, Solomon
SD. Right ventricular function is an independent predictor of death, heart
failure and stroke following myocardial infarction. Presented AHA 2004
Amigoni
M, Mangalat D, Bourgoun M, Velazquez E, Van de Werf
F, Ghali J, McMurray JJV, Kober
L, Pfeffer MA, Solomon SD. Mitral Regurgitation in
myocardial infarction complicated by heart failure, left ventricular
dysfunction or Both: Prognostic significance and relation to ventricular size
and function. Presented ACC 2005
Amigoni M, Mangalat D, Bourgoun M, Velazquez E,
Van de Werf F, Ghali J, McMurray JJV, Kober L, Pfeffer MA, Solomon SD. Left atrial size predicts
outcome in myocardial infarction complicated by heart failure, left ventricular
dysfunction or Both: Prognostic significance and
relation to ventricular size and function. Presented ESC 2005
E. Cardiac structure and function in Fabry’s Disease – response to Fabryzyme
Therapy: Sponsor, Genzyme
Echocardiographic
Analysis completed; Presented AHA 2004
eb
Page is Blank Page 2
II.
Ongoing Studies
A. Herceptin
Cardiomyopathy – Sponsor, NSABP/NCI and Genentech
Analyses
ongoing
B. Hypoxia Inducible
Factor I – Sponsor, Genzyme
Analyses
ongoing
C. Myocardial Fibroblast
Therapy Trial (MAGIC) – Sponsor, Genzyme
Analyses
ongoing
D. VALsartan
In Diastolic Dysfunction (VALIDD) Study – (S.Solomon, Study Chair); Sponsor, Novartis
E. ALiskiren
Failure Therapy (ALOFT) Trial ; Sponsor, Novartis
F. ALiskiren
to Alleviate LVH (ALLAY) Trial; (S.Solomon, Study Chair),
Sponsor, Novartis
G. Treatment of Preserved
Cardiac Function Heart failure with an Aldosterone Antagonist (TOPCAT) Trial –
(Core echo lab). Sponsor: NHLBI
H. DELTA-MI – Sponsor: Kai Pharmaceuticals
I. MADIT-CRT, Core echo lab,
Sponsor: Guidant